<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030342</url>
  </required_header>
  <id_info>
    <org_study_id>STLMC-IMM-0104</org_study_id>
    <secondary_id>CDR0000069153</secondary_id>
    <secondary_id>STLMC-L-01108</secondary_id>
    <secondary_id>NCI-V01-1686</secondary_id>
    <nct_id>NCT00030342</nct_id>
  </id_info>
  <brief_title>Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer</brief_title>
  <official_title>A Phase I/II Study Of Interleukin-12-Primed Activated T Cells In Combination With 5FU, GM-CSF And Interferon Alfa-2b In Metastatic Renal Cell Carcinoma Or Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies use different ways to stimulate the immune system and stop&#xD;
      cancer cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells&#xD;
      from dividing so they stop growing or die. Combining biological therapy with chemotherapy may&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of biological therapy combined with&#xD;
      chemotherapy in treating patients who have metastatic kidney cancer or colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety of a repeat course of interleukin-12-primed activated T cells&#xD;
           (12ATC) in combination with fluorouracil, sargramostim (GM-CSF), and interferon alfa-2b&#xD;
           in patients with metastatic renal cell or colorectal carcinoma.&#xD;
&#xD;
        -  Determine the clinical responses of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the efficacy of 12ATC in these patients.&#xD;
&#xD;
        -  Determine whether there are changes in immunologic parameters related to 12ATC as&#xD;
           measured by lymphocyte phenotype and cytokine secretion in these patients.&#xD;
&#xD;
        -  Determine the correlation between clinical responses in patients treated with this&#xD;
           regimen and in vitro immune functions of lymphocytes.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to disease type (renal cell carcinoma vs&#xD;
      colorectal carcinoma).&#xD;
&#xD;
      Patients receive sargramostim (GM-CSF) subcutaneously (SC) daily on days 1-5 and then undergo&#xD;
      collection of autologous peripheral blood mononuclear cells (PBMC) on days 6 and 7 of week 1.&#xD;
      The PBMC are treated ex vivo to form interleukin-12-primed activated T cells (12ATC).&#xD;
&#xD;
      Patients receive fluorouracil IV over 24 hours on day 6 of week 2 and interferon alfa-2b SC&#xD;
      and GM-CSF SC 3 times weekly on weeks 3-5. Patients receive 12ATC IV over 15-30 minutes twice&#xD;
      weekly and interferon alfa-2b SC (at least 24 hours after 12ATC infusion) once weekly on&#xD;
      weeks 6-8. Patients with complete or partial response or stable disease at 3 weeks after the&#xD;
      last 12ATC infusion may receive an additional 8-week course as above.&#xD;
&#xD;
      Patients are followed every 2-3 months for 1 year and then every 6 months for 2 years or at&#xD;
      any time when the physical examination or symptoms are suspicious for tumor progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 60 patients (30 per stratum) will be accrued for this study&#xD;
      within 2-3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Response as measured by RECIST guidelines and Kaplan-Meier method at 5 years</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival as measured by the Kaplan-Meier method at 5 years</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as measured by NCI common toxicity table at study completion</measure>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic renal cell carcinoma or&#xD;
             colorectal carcinoma, meeting 1 of the following criteria:&#xD;
&#xD;
               -  Obtained no benefit from prior standard or salvage therapy&#xD;
&#xD;
               -  Ineligible for standard therapy because of concurrent illness&#xD;
&#xD;
               -  Declined standard therapy&#xD;
&#xD;
          -  At least 1 site of measurable disease that can be measured in at least 1 dimension&#xD;
&#xD;
               -  At least 20 mm with conventional techniques OR at least 10 mm with spiral CT scan&#xD;
&#xD;
          -  No untreated or unstable, treated brain metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 4,000/mm^3&#xD;
&#xD;
          -  Granulocyte count at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
          -  No coagulation disorders&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.5 mg/dL*&#xD;
&#xD;
          -  ALT/AST less than 3 times upper limit of normal*&#xD;
&#xD;
          -  PT no greater than 1.5 times control (unless therapeutically anticoagulated)&#xD;
&#xD;
          -  PTT less than 1.5 times control (unless therapeutically anticoagulated) NOTE:&#xD;
             *Patients whose cancer has led to values that do not fall within the above ranges may&#xD;
             be eligible at the discretion of the investigators&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL* NOTE: *Patients whose cancer has led to values&#xD;
             that do not fall within the above range may be eligible at the discretion of the&#xD;
             investigators&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No thrombophlebitis&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  FEV_1 and FVC at least 65% predicted&#xD;
&#xD;
          -  No uncontrolled pulmonary embolism&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other malignancy within the past 5 years except resected basal cell skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No prior allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to interleukin-12-primed activated T cells or other study agents&#xD;
&#xD;
          -  No active autoimmune disease&#xD;
&#xD;
          -  No uncontrolled thyroid abnormalities&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No other uncontrolled concurrent illness&#xD;
&#xD;
          -  No psychiatric illness or social situations that would preclude study compliance&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for up to 2 years after&#xD;
             study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior steroid therapy or steroid-containing compounds&#xD;
&#xD;
          -  At least 2 weeks since prior topical or inhaled steroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent commercial anticancer agents&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P. Hanson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Luke's Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>February 14, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <responsible_party>
    <name_title>John P. Hanson, Jr</name_title>
    <organization>Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center</organization>
  </responsible_party>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

